17 November 2015 - A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral cancer therapies, including AstraZeneca's Iressa.
For more details, go to: http://www.reuters.com/article/2015/11/17/astrazeneca-cancer-tagrisso-idUSL8N13C1TU20151117#oaqsLdej5mURdZGp.97